Add to ORKGIn phase I development, CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and antitumor activity in head and neck squamous cell carcinoma (HNSCC), alone or in combination with cetuximab. Preliminary biomarker data raised the hypothesis of enhanced response in tumors harborin
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer among head and neck malignan...
peer reviewedMonoclonal antibodies are now part of the armamentarium available for the treatment of ...
BackgroundCetuximab combined with radiation therapy (RT) is an evidence-based treatment for locally ...
In phase I development, CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and ...
In phase I development, CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and ...
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous c...
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous c...
etuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous ce...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
BackgroundWe evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (...
Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Cen...
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer among head and neck malignan...
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer among head and neck malignan...
peer reviewedMonoclonal antibodies are now part of the armamentarium available for the treatment of ...
BackgroundCetuximab combined with radiation therapy (RT) is an evidence-based treatment for locally ...
In phase I development, CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and ...
In phase I development, CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and ...
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous c...
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous c...
etuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous ce...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
BackgroundWe evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (...
Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Cen...
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer among head and neck malignan...
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer among head and neck malignan...
peer reviewedMonoclonal antibodies are now part of the armamentarium available for the treatment of ...
BackgroundCetuximab combined with radiation therapy (RT) is an evidence-based treatment for locally ...